eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | severe combined immunodeficiency |
| Comorbidity | C0023418|leukemia |
| Sentences | 7 |
| PubMedID- 25635465 | [145] have used b43-pap immunotoxin plus cyclophosphamide to successfully treat human leukemia in mice with severe combined immunodeficiency (scid). |
| PubMedID- 23028826 | This has led to vector-mediated t cell leukemia in scid-x1 gene therapy trials, and also myeloid dysplasias in a chronic granulomatous disease clinical trial. |
| PubMedID- 23867470 | Engraftment of aml stem cell populations that highly express muc1 (muc1(high)) led to development of leukemia in nod-scid il2rgamma(null) (nsg) immunodeficient mice. |
| PubMedID- 22368270 | Nonobese diabetic/severe combined immunodeficiency mice transplanted with leukemia cells from patients before and during sorafenib resistance recapitulated the clinical results. |
| PubMedID- 21887305 | To evaluate the anti-leukemia effect of icaritin in vivo, nod-scid mice receiving 2×106 k562 cells inoculation were treated with icaritin. |
| PubMedID- 22135288 | It was reported that several patients developed t-cell leukemia during treatment of x-linked severe combined immunodeficiency (scid-x1), because of viral integration near the proto-oncogenes lmo2, bmi1 and ccnd2 (23,26). |
| PubMedID- 21182466 | The appearance of leukemia in x-scid treated patients [3-5] and of myelodysplasia in a clinical trial for chronic granulomatous disease (cgd) [6]. |
Page: 1